J. Goldman & Co’s Cymabay Therapeutics CBAY Stock Holding History

J. Goldman & Co’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-124,500	Closed	-$2.94M	–	557
2023 Q4	$2.94M	Sell	124,500 -10,500	-8%	-$187K	0.12%	163
2023 Q3	$2.01M	Buy	+135,000	New	+$1.79M	0.07%	202

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

J. Goldman & Co's CBAY Position: Q1 2024 in Review

J. Goldman & Co sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 165,937 shares — an estimated $3.92M sold.

J. Goldman & Co first reported a position in CBAY in Q3 2015 and held it in 14 quarters. The position peaked at $5.92M in Q1 2018. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

J. Goldman & Co reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
J. Goldman & Co sold 165,937 Cymabay Therapeutics shares in Q1 2024, an estimated $3.92M.
J. Goldman & Co first reported a position in Cymabay Therapeutics in Q3 2015 and held it in 14 quarters.
J. Goldman & Co's Cymabay Therapeutics position peaked at $5.92M in Q1 2018.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on J. Goldman & Co's 13F filing for Q1 2024, filed 15 May 2024.